loading page

Research Progress on Multi-Specific Antibodies against Newly Emerging Infectious Diseases
  • +2
  • Yutong Chen,
  • Yushan Jiang,
  • Bao Zhang,
  • Wei Zhao,
  • Chenguang Shen
Yutong Chen
Southern Medical University Guangdong Provincial Key Laboratory of Tropical Disease Research
Author Profile
Yushan Jiang
Southern Medical University Guangdong Provincial Key Laboratory of Tropical Disease Research
Author Profile
Bao Zhang
Southern Medical University Guangdong Provincial Key Laboratory of Tropical Disease Research
Author Profile
Wei Zhao
Southern Medical University Guangdong Provincial Key Laboratory of Tropical Disease Research

Corresponding Author:zhaowei@smu.edu.cn

Author Profile
Chenguang Shen
Southern Medical University Guangdong Provincial Key Laboratory of Tropical Disease Research
Author Profile

Abstract

In recent years, the world has witnessed in the emergence of several infectious diseases, with notable examples being coronavirus disease 2019 (COVID-19), avian influenza, and Mpox, which continue to present serious and persistent threats to global public health. The rapid spread and devastating impact of these diseases underscore the urgent need for effective combat strategies. One promising area of research in the field of antiviral drug development is the exploration of multi-specific antibodies. These have attracted significant attention owing to their diverse benefits compared to monoclonal antibodies. Multi-specific antibodies exhibit a more versatile function, possess a stronger binding affinity for viral targets, demonstrate enhanced antiviral activity, and show reduced susceptibility to viral escape mechanisms. These characteristics make them promising candidates for the development of novel antiviral therapies against a range of emerging infectious diseases. This review examines the current research progress surrounding multi-specific antibodies in the context of combating SARS-CoV-2, influenza virus, and other newly emerging infectious viruses. It offers insights into the potential applications and future prospects of multi-specific antibodies, with the aim to contribute to the ongoing efforts to address the global health challenges posed by infectious diseases.
Submitted to Influenza and other respiratory viruses
03 Jul 2024Reviewer(s) Assigned
25 Jul 2024Review(s) Completed, Editorial Evaluation Pending
25 Jul 2024Editorial Decision: Revise Major
31 Jul 20241st Revision Received
01 Aug 2024Submission Checks Completed
01 Aug 2024Assigned to Editor
16 Aug 2024Reviewer(s) Assigned